The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary

BACKGROUND: Fingolimod was approved and reimbursed by the healthcare provider in Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in 2012. The present study aimed to assess the effectiveness, safety profile, and persistence to fingolimod in a real-life setting...

Descripción completa

Detalles Bibliográficos
Autores principales: Biernacki, Tamás, Sandi, Dániel, Füvesi, Judit, Fricska-Nagy, Zsanett, Kincses, Tamás Zsigmond, Ács, Péter, Rózsa, Csilla, Dobos, Enikő, Cseh, Botond, Horváth, László, Nagy, Zsuzsanna, Csányi, Attila, Kovács, Krisztina, Csépány, Tünde, Vécsei, László, Bencsik, Krisztina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032373/
https://www.ncbi.nlm.nih.gov/pubmed/35452476
http://dx.doi.org/10.1371/journal.pone.0267346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032373/
https://www.ncbi.nlm.nih.gov/pubmed/35452476
http://dx.doi.org/10.1371/journal.pone.0267346

Ejemplares similares